Black checkmark with a sparkle and a curved line underneath on a white background.
Company

CDT Equity Inc.

Ticker
CDT
Sector
Industry
Report date
November 17, 2026
Valye AI Score

67

High visibility
Recent developments
Recent developments summary

Recent developments highlight CDT's strategic investments and patent activities focused on AI-driven drug development and expansion into respiratory and animal health markets.

Recent developments:
  • CDT highlighted Sarborg patent filings targeting a $20 billion respiratory market, emphasizing AI-driven innovation in drug development [N1].
  • The company acquired a 20% stake in Sarborg to expand its AI offerings, strengthening its technological capabilities [N2].
  • Conduit Pharmaceuticals filed patents for AZD5658 and new combination patents for AZD1656 and AZD5658 in collaboration with Sarborg Limited, enhancing its intellectual property portfolio [N3].
  • CDT entered a joint development deal with Manoira Corporation to explore opportunities in the animal health market, diversifying its pipeline [N4].
  • The company regained Nasdaq compliance and completed reverse stock splits to meet listing requirements, addressing regulatory obligations [N5][N6].
  • CDT secured a Korean patent for AZD1656, advancing its global development strategy for autoimmune disorders [N7].
  • Andrew Regan was appointed CEO, succeeding David Tapolczay, indicating leadership continuity and strategic focus [N8].
Overview

CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., is a Delaware-based pharmaceutical development company that focuses on identifying and advancing clinical-stage therapeutic assets through scientific innovation and strategic partnerships. The company uses artificial intelligence, solid-form chemistry, and asset repositioning to accelerate drug development. Its strategy targets clinical-stage compounds deprioritized by larger pharmaceutical companies, improving drug properties and extending patent life via proprietary solid-form technologies developed at its Cambridge facilities. CDT collaborates with Sarborg Limited to apply AI-powered disease mapping for rapid identification of new therapeutic applications and combinations. The pipeline includes candidates for autoimmune disorders, idiopathic male infertility, oncology, dermatology, rare diseases, and animal health. The company operates with a lean, asset-agnostic model, avoiding costly clinical trials by focusing on high-leverage development strategies. CDT holds licenses from AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 and myeloperoxidase inhibitor AZD5904, responsible for their further development and commercialization. Partnerships with Manoira Corporation enable exploration of veterinary applications while retaining human IP rights. Financially, as of September 30, 2026, CDT reported $1.723 million in cash and equivalents, current liabilities exceeding current assets, and a net loss of $13.287 million for the nine months ended September 30, 2026.

Executive summary

CDT Equity Inc. is a pharmaceutical development company focused on advancing clinical-stage therapeutic assets using AI, solid-form chemistry, and strategic partnerships. The company operates a lean, asset-agnostic model emphasizing capital efficiency and speed. Key partnerships include Sarborg Limited for AI-driven drug repurposing and Manoira Corporation for animal health market expansion. CDT holds licenses from AstraZeneca for several clinical assets and leverages prior clinical trial data for development. Financially, as of September 30, 2026, the company reported $1.723 million in cash and equivalents, a current ratio of 0.2, and a net loss of $13.287 million for the nine months ended. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for CDT

Bull case model:

CDT's business model leverages AI and solid-form chemistry to unlock value in clinical-stage compounds with existing safety data, potentially accelerating development timelines and reducing costs. The partnership with Sarborg Limited provides proprietary AI-driven decision-support tools and disease mapping capabilities that inform pipeline development and patent filings, enhancing intellectual property strength. The company's licensing agreements with AstraZeneca for multiple clinical assets provide a foundation for pipeline advancement. Expansion into the animal health market through Manoira Corporation offers diversification opportunities. Recent patent filings and strategic investments in Sarborg underscore a commitment to innovation and AI integration, which may differentiate CDT in the pharmaceutical development sector.

Bear case model:

CDT operates with a lean model but faces significant financial challenges, including a current ratio of 0.2 and net losses exceeding $13 million for the nine months ended September 30, 2026, indicating liquidity constraints. The company's reliance on successful pre-clinical trials and subsequent licensing deals introduces execution risk, as there is no assurance of trial success or licensing revenue. The complex relationships with related parties such as Sarborg and Manoira may pose governance and conflict-of-interest risks. Additionally, the company's strategy to avoid costly clinical trials may limit its control over later-stage development and commercialization. Market acceptance of repurposed drugs and AI-driven development approaches remains uncertain, potentially impacting future value realization.

Moat:

CDT's moat derives from its integration of advanced AI-driven drug repurposing technologies through its partnership with Sarborg Limited, proprietary solid-form chemistry capabilities that extend patent life by up to 20 years, and strategic licensing agreements with AstraZeneca for clinical-stage assets. The company's lean, asset-agnostic model allows capital-efficient development focused on high-potential compounds deprioritized by larger pharmaceutical companies. Its ability to leverage existing clinical safety data and AI insights to identify novel therapeutic applications and combinations provides a competitive advantage in accelerating drug development and intellectual property creation. Additionally, the joint development agreement with Manoira Corporation expands its reach into the animal health market, potentially diversifying revenue streams while retaining core human therapeutic IP.

Risks overview
Risks summary
CDT faces significant liquidity constraints and execution risks related to clinical development success and reliance on related-party partnerships, which may impact its operational and strategic outcomes.
Risks details:

• Financial Liquidity Risk: As of September 30, 2026, CDT reported a current ratio of 0.2 and cash ratio of 0.1, indicating limited short-term liquidity relative to current liabilities, which may constrain operational flexibility.
• Clinical and Development Risk: The company depends on successful pre-clinical trials to advance assets and secure licensing deals. There is no assurance that these trials will be successful or that licensing agreements will be secured.
• Related Party and Governance Risk: Close relationships with related parties such as Sarborg Limited and Manoira Corporation, including shared leadership, may present conflicts of interest and governance challenges.
• Market and Commercialization Risk: CDT's strategy to license assets post pre-clinical trials means it relies on third parties for later-stage development and commercialization, which may affect control and revenue realization.

FINAL FORECAST FOR CDT

Final take one line
CDT Equity Inc. operates a data-driven pharmaceutical development platform leveraging AI and solid-form chemistry with strong strategic partnerships but faces liquidity and execution risks.
Final take 12 to 24 month view

Business trends: Increasing integration of AI technologies and expansion into respiratory and animal health markets through strategic partnerships and patent filings.
Execution milestones: Completion of Sarborg service phases, acquisition of Sarborg stake, patent filings for key assets, and regulatory compliance actions.
Key risks: Financial liquidity constraints, reliance on successful pre-clinical trials and licensing, related-party governance complexities, and market commercialization uncertainties.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

67
LLM visibility overview
LLM Visibility known facts
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-15 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-10-14 | www.nasdaq.com | CDT Highlights Sarborg Patent Filing Targeting $20 Billion Respiratory Market | https://www.nasdaq.com/articles/cdt-highlights-sarborg-patent-filing-targeting-20-billion-respiratory-market
  • N2 | 2026-02-20 | www.nasdaq.com | CDT Equity To Buy 20% Stake In Sarborg To Expand AI Offerings | https://www.nasdaq.com/articles/cdt-equity-buy-20-stake-sarborg-expand-ai-offerings
  • N3 | 2025-07-07 | www.nasdaq.com | Conduit Pharmaceuticals Files First Patent for AZD5658 and New Combination Patents for AZD1656 and AZD5658 in Collaboration with Sarborg Limited | https://www.nasdaq.com/articles/conduit-pharmaceuticals-files-first-patent-azd5658-and-new-combination-patents-azd1656-and
  • N4 | 2025-06-04 | www.nasdaq.com | Conduit Pharma In Joint Development Deal With Manoira To Enter Into Animal Health Market | https://www.nasdaq.com/articles/conduit-pharma-joint-development-deal-manoira-enter-animal-health-market
  • N5 | 2025-05-22 | www.nasdaq.com | Conduit Pharma Gains Nasdaq Capital Market Approval, Transfer Effective May 23 | https://www.nasdaq.com/articles/conduit-pharma-gains-nasdaq-capital-market-approval-transfer-effective-may-23
  • N6 | 2025-05-21 | www.nasdaq.com | Conduit Pharmaceuticals Inc. Regains Compliance with Nasdaq Listing Requirements | https://www.nasdaq.com/articles/conduit-pharmaceuticals-inc-regains-compliance-nasdaq-listing-requirements
  • N7 | 2025-05-09 | www.nasdaq.com | Conduit Pharmaceuticals Secures Korean Patent for AZD1656, Advancing Global Development Strategy for Autoimmune Disorders | https://www.nasdaq.com/articles/conduit-pharmaceuticals-secures-korean-patent-azd1656-advancing-global-development
  • N8 | 2025-04-16 | www.nasdaq.com | Conduit Pharma Appoints Andrew Regan To Succeed David Tapolczay As CEO | https://www.nasdaq.com/articles/conduit-pharma-appoints-andrew-regan-succeed-david-tapolczay-ceo
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine